STAT+: Pharma is still struggling to widen access to medicines — and reach patients — in low- and middle-income countries
Amid calls to expand access to medicines in low- and middle-income countries, a new analysis…
Category: STAT+
STAT+: Viridian drug achieves study goals as treatment for thyroid eye disease
Viridian Therapeutics said Tuesday that an experimental treatment improved the signs and symptoms of thyroid…
.jpg)
STAT+: Roivant acquires drug for pulmonary hypertension from Bayer
For months, investors have been asking Roivant Sciences chief executive Matt Gline to reveal the…
STAT+: Former Verily executives hatch plan to invest millions in high-tech medical data
Two former Verily executives say that they are starting a new initiative, Highlander Health, to…
STAT+: House passes bill that targets China biotechs
WASHINGTON — The House Monday passed a bill by 306 to 81 votes to make…
STAT+: How powerful hospitals helped take R1 RCM private
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: Merck executive plays down impact of new lung cancer drug data on Keytruda
With strong data released over the weekend, an experimental Chinese drug showed it could one…
STAT+: RayzeBio, Dice alums raise $370 million for new autoimmune startup
After leading his previous company through a back-to-back IPO and M&A deal, the former chief…
STAT+: Highmark reboots coverage of digital treatments, raising hope among DTx companies
Highmark Health, a large regional health insurer that also owns a chain of hospitals, is…
STAT+: Relay discloses encouraging results for experimental breast cancer treatment
Relay Therapeutics disclosed encouraging results for its key breast cancer drug and plans to advance…
STAT+: With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights
On Sunday, a small biotech company called Summit Therapeutics won a remarkable victory, saying its…
STAT+: Detailed data show Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial
SAN DIEGO — For years, Merck’s drug Keytruda has dominated cancer immunotherapy, racking up dozens…
STAT+: Ascension, other hospitals played active roles to take medical billing company R1 RCM private
Private equity firms are leading the buyout of R1 RCM, a major provider of billing…
STAT+: Pharmalittle: We’re reading about FDA inspections, Lilly insulin trial results, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Vor Biopharma’s ‘shielded’ transplant delays relapse in leukemia patients
A CRISPR-augmented stem cell transplant that protects healthy cells from the toxic effects of anti-cancer…
STAT+: U.K. charities give $36 million to start new drugs for childhood tumors
For three decades, adults have benefited from a revolution in oncology treatment, as immunotherapies and…
STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Summit Therapeutics vs. Merck: Prepping for a big lung cancer study reveal
Let’s set the table for Sunday’s presentation of the lung cancer immunotherapy trial known as…
STAT+: Alnylam versus BridgeBio: The ATTR-CM debate
I coined the term “Typo-gate” to describe the misguided dustup Alnylam Pharmaceuticals executives instigated last…
STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target
Nearly two decades ago, a small company called Amylin Pharmaceuticals saw that its first commercial…
STAT+: Humana cutting Medicare Advantage plans that cover 10% of members
Roughly 10% of people enrolled in Humana’s private Medicare plans will have to find new…
STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Novartis to spend $200 million in further bid to boost radiopharma manufacturing, market dominance
Novartis is opening a new manufacturing facility in California and expanding an existing production site…
STAT+: Drug aimed at strengthening neurons to treat Alzheimer’s fails in trial
A dark horse effort to treat Alzheimer’s disease, already marred by a data manipulation scandal,…
STAT+: Greece’s antitrust regulator probes Novartis over practices tied to a pricey eye drug
Greece’s antitrust regulator is investigating allegations that, over a nine-year period, Novartis paid doctors and…
STAT+: Vaxcyte shares boom as one of biotech’s big David vs. Goliath stories heats up
With new vaccine data released Tuesday, Vaxcyte, a San Carlos, Calif.-based firm, emerged as one…
STAT+: Dana-Farber CEO Laurie Glimcher to step down, saying ‘we must look to the next generation’
Laurie H. Glimcher, chief executive of Dana-Farber Cancer Institute, said she would step down next…
STAT+: Pharmalittle: We’re reading about Medicare drug prices, a Sanofi MS pill, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Recursion presents mixed data on lead AI-derived drug candidate for potentially fatal brain condition
Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that,…
STAT+: European court sides with Illumina, saying regulators overstepped in scrutiny of Grail deal
LONDON — Europe’s top court on Tuesday ruled that regulators overstepped in challenging the DNA…
STAT+: Diagnosed with cancer, a pharmaceutical executive became a patient advocate and changed drug development. It took decades
Kathy Giusti was diagnosed with multiple myeloma in 1996, when she was a 37-year-old executive…
STAT+: At major cardiology conference, Wegovy’s the word
LONDON — When Europe’s largest cardiology conference opened here this past Friday, one of the…
STAT+: Sanofi says its new pill for multiple sclerosis succeeded in a key trial, boosting its research ambitions
Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a…
STAT+: HCA and UnitedHealth resolve contract disputes in four states hours before deadline
HCA Healthcare and UnitedHealthcare reached agreements just hours before their contracts were scheduled to expire…
STAT+: A ‘tie-breaker’ study of Abbott’s heart clip brings more questions than answers
A study meant to serve as a tie-breaker between two major trials of a heart…
STAT+: Pharmalittle: We’re reading about Wegovy study results, an Alnylam heart drug, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Detailed data on Alnylam’s heart drug show substantial benefit, while competition likely awaits
LONDON — An experimental drug from Alnylam Pharmaceuticals substantially cut the risk of death and…
STAT+: Wegovy cut patients’ chances of dying from Covid-19, new analysis shows
LONDON — Novo Nordisk made worldwide headlines last year when a study demonstrated that Wegovy,…
STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure
Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a…
STAT+: Thoughts, takes, and burning biotech questions as the beginning of the end of the year approaches
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Pharmalittle: We’re reading about Zepbound pricing caveats, PBM congressional testimony, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends?
Hims & Hers, one of the largest publicly traded telehealth companies in the country, has…
STAT+: Pharmalittle: We’re reading about Zantac court cases, a Neurocrine schizophrenia pill, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Neurocrine reports mixed results on schizophrenia therapy in mid-stage trial
Neurocrine Biosciences said Wednesday that the lowest dose of an experimental pill for schizophrenia reduced…
STAT+: UnitedHealth pledged a hands-off approach after buying a Connecticut medical group. Then it upended how doctors practice
MIDDLETOWN, Conn. — UnitedHealth Group told the Connecticut primary care doctors everything they wanted to…
STAT+: Centene eliminates brokers’ commissions for Medicare drug plans
Health insurer Centene will not pay any commissions to brokers and agents who help people…
STAT+: Pharmalittle: We’re reading about Lilly cutting Zepbound’s price; Pfizer selling direct to consumers, and more
Good morning, everyone, and how are you today? We are just fine, thank you, especially…
STAT+: Lilly launches Zepbound vials in move that could ease supply constraints
Eli Lilly said Tuesday that it will start providing low-dose vials of its obesity drug…
STAT+: To help migraine patients — and sell more medicines — major drugmakers turn to telehealth
In 2021, Katey Frederking had reached the end of her rope. The 29-year-old was struggling…
STAT+: Continuous glucose monitoring for the masses is here. Are we ready for it?
NEW YORK — Glucose tracking is the future, Dexcom executives gushed at a glitzy launch…